$SION

Sionna Therapeutics, Inc.

Sionna Therapeutics is a clinical-stage biopharmaceutical company developing medicines for people with cystic fibrosis. Its research focuses on stabilizing the CFTR protein’s NBD1 domain, which is affected by the common F508del mutation, and on developing complementary CFTR modulators for combination treatments. Its pipeline includes SION-719, an NBD1 stabilizer being studied with the standard of care in a Phase 2a trial, and SION-451, an NBD1 stabilizer in Phase 1 combination trials with SION-2222 and SION-109. Other candidates include the correctors SION-2222, SION-109 and SION-2851, and the potentiator SION-3067. Sionna is developing these medicines for potential use in proprietary combinations or alongside existing CF treatments. It is headquartered in Waltham, Massachusetts.

AlphAI earnings readsecond quarter 2026 · AUG 6Sionna Therapeutics Reports Second Quarter 2026 Financial ResultsVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
1
1

No SEC Form 4 filings for $SION in the last 30 days.

See all $SION insider activity →
Low

Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals

InspireMD (NSPR) received FDA approval for its TCAR stent, while Eli Lilly (LLY) and Bayer (BAYRY) secured approvals for obesity and stroke drugs. Johnson & Johnson (JNJ) won FDA approval for a head and neck cancer treatment. Meanwhile, Sionna (SION), Nano-X (NNOX), and Coherus (CHRS) announced workforce reductions. Pfizer (PFE) and Blackstone agreed to co-fund an obesity drug. Key stock prices were reported.

Sionna Reports Q3 2026 Results, Advances CF Combination Trial for 2027

Sionna reported a Q3 2026 net loss of $32.4M, up from $20.3M a year earlier, with operating expenses rising. The company has $249.8M in cash, expected to last until mid-2029. Sionna plans to start a Phase 2 trial of its SION-451 and SION-2222 combination in Q1 2027, focusing on cystic fibrosis treatment.

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. Sionna Therapeutics Reports Third Quarter 2026 Financial Results Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027 Clinical and nonclinical data presented at 2026 NACFC support advance

SION sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SION (Sionna Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.

Recent SION coverage spans corporate actions, regulation and earnings.

What's driving SION

AlphAI scores every news story that mentions SION with an AI model for sentiment and relevance, and aggregates insider trades from Sionna Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SION

Score

Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals

InspireMD (NSPR) received FDA approval for its TCAR stent, while Eli Lilly (LLY) and Bayer (BAYRY) secured approvals for obesity and stroke drugs. Johnson & Johnson (JNJ) won FDA approval for a head and neck cancer treatment. Meanwhile, Sionna (SION), Nano-X (NNOX), and Coherus (CHRS) announced workforce reductions. Pfizer (PFE) and Blackstone agreed to co-fund an obesity drug. Key stock prices were reported.

$SIONMedEarnings

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. Sionna Therapeutics Reports Third Quarter 2026 Financial Results Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027 Clinical and nonclinical data presented at 2026 NACFC support advance

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Sionna Therapeutics (Nasdaq: SION) will present data at the 2026 North American Cystic Fibrosis Conference. The company reported post hoc analyses of the PreciSION CF trial, showing an 8.6 mmol/L sweat chloride reduction with SION-719. Sionna plans to advance SION-451 + SION-2222 into a Phase 2a trial in early 2027. Preclinical data suggests potential benefits for a broad CF population.

RA CAPITAL MANAGEMENT, L.P. (Kolchinsky Peter, Shah Rajeev M.) sold $21.8M of SION (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. sold 3,448,811 indirectly-held shares of Sionna Therapeutics, Inc. (SION) at an average of $6.33 ($6.32–$7.46, $21.84M total) across 2 trades on 2026-09-17. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund, L.P. (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

Why is Sionna Therapeutics stock sliding today?

Sionna Therapeutics' stock fell 3% after-hours following a strategic reset, including a 46% workforce reduction and a shift in clinical trial focus. The company also confirmed it will not pursue SION-719. Raymond James downgraded the stock to Market Perform. The broader market showed minimal gains, with the S&P 500, Dow Jones, and Nasdaq each rising 0.1% or 0.2%.

$SIONMedClinical / regulatory· trial start

Sionna Therapeutics, Inc. (SION): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NB

Related tickers